After two patient deaths from presumed sepsis, FDA puts partial hold on Zentalis studies
The FDA put three clinical studies of Zentalis’ WEE1 inhibitor on partial hold following two patient deaths likely from sepsis in one study earlier this …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
